Clinical Trial Detail

NCT ID NCT02826434
Title Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Poly ICLC + PVX-410

Age Groups: adult senior

No variant requirements are available.